Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.72
-0.7%		$1.28
$0.67
▼
$2.44
$29.40M0.48276,502 shs14,839 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.49
+1.5%		$5.20
$1.39
▼
$27.15
$26.67M1.692,865 shs49,381 shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.07
$0.09
$0.06
▼
$0.77
$30.66M1.38.10 million shsN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$5.93
+23.7%		$5.01
$3.53
▼
$5.76
$7.88M1.3776,658 shs3.10 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00%-14.18%-35.71%-54.13%-59.09%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%-6.96%-65.00%-86.34%-90.67%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%0.00%0.00%-57.54%-87.38%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00%0.00%0.00%0.00%+22.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.72
-0.7%		$1.28
$0.67
▼
$2.44
$29.40M0.48276,502 shs14,839 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.49
+1.5%		$5.20
$1.39
▼
$27.15
$26.67M1.692,865 shs49,381 shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.07
$0.09
$0.06
▼
$0.77
$30.66M1.38.10 million shsN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
$5.93
+23.7%		$5.01
$3.53
▼
$5.76
$7.88M1.3776,658 shs3.10 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
0.00%-14.18%-35.71%-54.13%-59.09%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
0.00%-6.96%-65.00%-86.34%-90.67%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%0.00%0.00%-57.54%-87.38%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.00%0.00%0.00%0.00%+22.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
2.50
Moderate Buy$247.5016,488.47% Upside
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
1.75
Reduce$5.507,332.43% Upside
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest TTNP, SGMO, ENLV, and BYSI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/21/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/26/2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
(Data available from 8/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/A$0.11 per share6.34($0.59) per shareN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$122.21 per shareN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$39.55M0.78N/AN/A($0.04) per share-1.85
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/A$2.67 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.12N/AN/AN/AN/AN/A-28.88%11/12/2026 (Estimated)
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.24B-$8.25N/AN/AN/AN/A248.08%206.39%8/24/2026 (Estimated)
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$122.93M-$0.38N/AN/AN/A-310.81%-2,662.06%-132.12%N/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
-$4.71M-$2.95N/AN/AN/AN/A-108.60%-95.64%N/A

Latest TTNP, SGMO, ENLV, and BYSI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/24/2026Q1 2026
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.31N/AN/AN/AN/AN/A
8/14/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.02+$0.52-$0.02$8.77 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
0.70
0.70
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
193.24
193.24
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.84
0.84
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
N/A
11.60
11.60

Institutional Ownership

CompanyInstitutional Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
1.02%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
56.92%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
31.49%

Insider Ownership

CompanyInsider Ownership
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
12.28%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4.10%
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
0.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
8041.12 million29.07 millionOptionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7017.49 million15.34 millionOptionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480414.29 million397.29 millionOptionable
Titan Pharmaceuticals, Inc. stock logo
TTNP
Titan Pharmaceuticals
101.33 million1.32 millionOptionable

Recent News About These Companies

Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation
October 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/10/03/3161232/0/en/Titan-Pharmaceuticals-Inc-Announces-Closing-of-Merger-with-Black-Titan-Corporation.html
Titan Pharmaceuticals Approves Merger with Black Titan
August 26, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/titan-pharmaceuticals-approves-merger-with-black-titan/ar-AA1Lh9MA
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP
August 5, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250805537084/en/titan-pharmaceuticals-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-merger-of-titan-pharmaceuticals-inc.---ttnp/
URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
July 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/29/3123457/0/en/urgent-the-m-a-class-action-firm-encourages-hareholders-to-act-before-vote-titan-pharmaceuticals-inc-nasdaq-ttnp.html
Titan Pharmaceuticals Inc (TTNP) - Investing.com
July 4, 2025  |  investing.comhttps://www.investing.com/equities/titan-pharma-inc-financial-summary
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - Morningstar
June 29, 2025  |  morningstar.comM
Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - Nasdaq
June 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/titan-pharmaceuticals-completes-private-placement-series-c-convertible-preferred-stock
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
June 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/titan-pharmaceuticals-announces-600-000-200500134.html
Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management
June 27, 2025  |  quiverquant.comQ
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock
June 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/27/3106813/0/en/titan-pharmaceuticals-announces-600-000-private-placement-of-convertible-preferred-stock.html
titan pharmaceuticals issues common stock following preferred stock conversions
June 4, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/titan-pharmaceuticals-issues-common-stock-following-preferred-stock-conversions-93CH-4076860
Titan announces filing of registration statement for proposed combination
June 4, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/titan-announces-filing-registration-statement-125019487.html
Titan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.
June 3, 2025  |  quiverquant.comQ
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.
June 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/03/3092778/0/en/titan-pharmaceuticals-announces-filing-of-registration-statement-for-proposed-business-combination-with-talentec-sdn-bhd.html
Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock
April 11, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/11/3060338/0/en/titan-pharmaceuticals-announces-1-million-private-placement-of-convertible-preferred-stock.html
Titan Pharmaceuticals: Q4 Earnings Snapshot
March 20, 2025  |  sfgate.comhttps://www.sfgate.com/business/article/titan-pharmaceuticals-q4-earnings-snapshot-20232826.php
Titan Pharmaceuticals receives Nasdaq notice of non-compliance
November 27, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/titan-pharmaceuticals-receives-nasdaq-notice-of-non-compliance-1034073513
Titan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee Requirements
November 27, 2024  |  quiverquant.comQ
Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq
November 27, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/27/2988437/0/en/titan-pharmaceuticals-inc-announces-receipt-of-notice-from-nasdaq.html
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
October 25, 2024  |  msn.comhttps://www.msn.com/en-us/money/markets/sanofi-eyes-breakout-after-pharma-titan-rides-vaccine-sales-to-quarterly-beat/ar-AA1sV5cM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.72 -0.01 (-0.71%)
As of 10:28 AM Eastern
This is a fair market value price provided by Massive. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.49 +0.02 (+1.50%)
As of 10:32 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)
As of 08/21/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Titan Pharmaceuticals stock logo

Titan Pharmaceuticals NASDAQ:TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas